LUCIRA™ HEALTH Hires Chief Revenue Officer Kevin Collins
May 28 2021 - 6:00AM
Business Wire
Appointment expands Lucira’s management team
with medtech veteran
Lucira Health, Inc. (Nasdaq: LHDX), a medical technology company
focused on the development and commercialization of transformative
and innovative infectious disease test kits, today announced
medtech veteran Kevin Collins has joined the company as Chief
Revenue Officer with global revenue responsibility.
Collins began his medical technology career with Lumenis Ltd., a
medical equipment and laser technologies company, where he rose
from Area Sales Manager to Regional Sales Manager for lasers in two
years. In 2009, he joined Intutive Surgical, Inc., a world leader
in medical robotics. In 2017 he was named Vice President, Global
Distribution Markets, driving the adoption of da Vinci surgical
robots across 36 countries while generating revenue growth. Most
recently, he was Vice President of International Commercial
Operations at Outset Medical, Inc., which is introducing innovative
dialysis technology.
Lucira CEO Erik Engelson said, “We are delighted that Kevin is
joining our management team. He’s an experienced global business
leader who has increased sales in every stage of his dynamic
career. Our testing platform dovetails perfectly with his expertise
and commitment to improving healthcare.”
About Lucira Health, Inc.
Lucira is a medical technology company focused on the
development and commercialization of transformative and innovative
infectious disease test kits. Lucira’s testing platform produces
lab quality molecular testing in a single-use, consumer-friendly,
palm-size test kit powered by two AA batteries. Lucira designed its
test kits to provide accurate, reliable and on-the-spot molecular
test results anywhere and at any time. The LUCIRA™ CHECK IT
COVID-19 Test Kit (OTC) and LUCIRA™ COVID-19 All-In-One Test Kit
(Rx) are designed to provide a clinically relevant COVID-19 result
within 30 minutes from sample collection.
Forward Looking Statements
Statements contained in this press release regarding matters
that are not historical facts are “forward-looking statements”
within the meaning of the Private Securities Litigation Reform Act
of 1995. Such forward-looking statements include statements
regarding, among other things, Lucira’s continued development and
commercialization of its transformative and innovative infectious
disease test kits and ability to increase sales. Because such
statements are subject to risks and uncertainties, actual results
may differ materially from those expressed or implied by such
forward-looking statements. Words such as “can” “plans,” “will,”
“may,” “anticipates,” “expects,” “potential” and similar
expressions are intended to identify forward-looking statements.
These forward-looking statements are based upon Lucira’s current
expectations and involve assumptions that may never materialize or
may prove to be incorrect. Actual results could differ materially
from those anticipated in such forward-looking statements as a
result of various risks and uncertainties, including the impact to
our business of the ongoing COVID-19 pandemic; any impact on our
ability to market our products; demand for our products due to
deferral of procedures using our products or disruption in our
supply chain; our ability to achieve or sustain profitability; our
ability to gain market acceptance for our products and to
accurately forecast and meet customer demand; our ability to
compete successfully; our ability to enhance our product offerings;
development and manufacturing problems; capacity constraints or
delays in production of our products; maintenance of coverage and
adequate reimbursement for procedures using our products; and
product defects or failures. These and other risks and
uncertainties are described more fully in the “Risk Factors”
section and elsewhere in our filings with the Securities and
Exchange Commission and available at www.sec.gov, including in our
most recent Annual Report on Form 10-K and Quarterly Report on Form
10-Q. Any forward-looking statements that we make in this
announcement speak only as of the date of this press release, and
Lucira assumes no obligation to update forward-looking statements
whether as a result of new information, future events or otherwise
after the date of this press release, except as required under
applicable law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210528005067/en/
Lucira Health Media Contact Kevin Knight 206-451-4823
media@lucirahealth.com
Lucira Health Investor Contact Greg Chodaczek 347-620-7010
investorrelations@lucirahealth.com
Lucira Health (NASDAQ:LHDX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Lucira Health (NASDAQ:LHDX)
Historical Stock Chart
From Sep 2023 to Sep 2024